tapebrief
HSIC · Q2 2025

HSIC · Q3 2025 Earnings

Bullish

Henry Schein

Reported November 4, 2025

30-second summary

Henry Schein raised FY2025 non-GAAP EPS guidance to $4.88–$4.96 (from $4.80–$4.94) and lifted the low end of sales growth to 3%–4% (from 2%–4%) after Q3 revenue grew 5.2% YoY to $3.34B and non-GAAP EPS came in at $1.38. Management quantified the previously vague Capstone/consultant workstream as a $200M net operating income improvement "over the next few years," and the tone shifted sharply from last quarter's "2025 is a base year" reset to "the distribution part of Henry Schein has gained momentum. It's back in its stride. We're winning." The 2026 recovery narrative now has both numbers and conviction behind it.

Headline numbers

EPS

Q3 FY2025

$1.38

Revenue

Q3 FY2025

$3.34B

+5.2% YoY

Gross margin

Q3 FY2025

30.7%

Operating margin

Q3 FY2025

4.9%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$3.34B+5.2%$3.24B+3.1%
EPS$1.38—$1.10+25.5%
Gross margin30.7%—31.4%-70bps
Operating margin4.9%—4.7%+20bps

Guidance

Henry Schein raised FY2025 non-GAAP EPS guidance to $4.88–$4.96 (from $4.80–$4.94) and increased sales growth low-end to 3%–4% (from 2%–4%), citing sales acceleration and market share gains across segments.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Non-GAAP Diluted EPS
FY2025
$4.80 to $4.94$4.88 to $4.96Low end raised $0.08, high end raised $0.02; midpoint raised $0.05Raised
Total Sales Growth
FY2025
2% to 4%3% to 4%Low end raised 100bpsRaised

Reaffirmed unchanged this quarter: Adjusted EBITDA Growth (mid-single digits)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Global Distribution and Value-Added Services$2.84B+4.8%
Global Specialty Products$0.369B+5.9%
Global Technology$0.173B+9.7%
Global Dental Distribution$1.714B+4.8%
Global Medical Distribution$1.126B+4.7%

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Adjusted EBITDA$295 million
Internal Sales Growth3.3%
Acquisition Sales Growth0.7%
FX Impact on Sales1.2%

Management tone

Q1 cyber-incident recovery → Q2 strategic reset and CEO transition → Q3 momentum regained with $200M number attached.

The defensive frame is gone. One quarter ago management called 2025 a "base year" and outsourced the margin fix to two consulting firms with results "towards the beginning of 2026." This quarter the anchor quote is "The distribution part of Henry Schein has gained momentum. It's back in its stride. We're winning." That is not the language of a company managing through a strategic reset — it's the language of a company that believes the reset is working ahead of schedule. The 5.2% revenue print and 140bps acceleration in internal sales growth give the rhetoric empirical support.

The Capstone/consultant workstream now has a number. In Q2, management promised "mathematical targets" later and would not size the 2026 benefit. This quarter, the company put $200M of net operating income improvement on the table, explicitly described as "over the next few years." The verbatim framing — "this $200 million of operating income improvement... it is net... over time, we think that this is a $200 million net opportunity" — is a meaningful commitment for a company that had been deferring quantification. Against a current operating income base implied by ~4.9% margin on ~$13.5B run-rate revenue (~$660M), a $200M net add is roughly 30% expansion potential, which reframes the 2026+ earnings trajectory.

Pricing and competitive dynamics have inverted from defensive to offensive. Q2's narrative was glove pricing as a structural drag and customer retention through a "frequent buyer" affinity program. This quarter management said "this time now we don't see pricing going down too much. It's pretty stable... we believe we're gaining market share" and disclosed that "salespeople are knocking on our door from our competitors, just not one, but multiple competitors." Sales-rep poaching is a leading indicator of competitive momentum and corroborates the share-gain claim more credibly than internal sales metrics alone.

KKR has moved from passive stake to active operating partner. Last quarter KKR was mentioned in the context of board representation and Capstone advisory. This quarter management described "two members on the board are very active," Capstone selecting the two outside consulting firms, and ongoing input on "best practices" to management. The KKR relationship is now substantively embedded in execution, not just capital structure — which matters for an incoming CEO inheriting both the relationship and the $200M target.

Tariff inflation, framed as a developing risk in Q2, is now characterized as contained. Management quantified tariff inflation at "100 or so basis points" and cited specific mitigation: manufacturer absorption, switching some products to U.S. manufacturing. The hedging language ("it's hard to tell where this is going to go") remains, but the operational response is concrete.

Recurring themes management leaned on this quarter:

Post-cyber recovery and momentum restorationMarket share gains across distribution, implants, and softwareMargin stabilization in dental and medical segmentsValue creation program ($200M operating income target)Specialty products growth in value implants diluting premium marginsKKR strategic partnership deepening through board representation and operational collaboration

Risks management surfaced:

Value implant growth diluting premium implant marginsMedical segment mix pressure from lower-margin pharmaceutical and vaccine salesTiming variability in respiratory season affecting Q4 medical salesTariff inflation and potential further escalation requiring ongoing mitigationCustomer alternate sourcing risk post-cyber incident (largely mitigated but referenced)

Answers to last quarter's watch list

Distribution gross margin trajectory — Consolidated gross margin fell to 30.7% from 31.4% in Q2 (-70bps QoQ), but distribution revenue accelerated to +4.8% from +2.9% and operating margin expanded 20bps QoQ to 4.9%. Management framed pricing as "pretty stable" with tariff inflation at ~100bps offset through mitigation. Margin compression is contained to mix (value implants, pharma/vaccines) rather than competitive pricing, and the EPS raise validates that the FY $4.92 midpoint is no longer at risk.
Resolved positively
Quantified Capstone/KKR targets — Delivered. Management put $200M of net operating income improvement on the table "over the next few years," with the workstream now characterized as a formal "value creation program" supplementing Bold+1. The number is not yet broken into 2026 vs out-year contribution, but the commitment itself is a material disclosure step.
Resolved positively
Q3 EPS growth confirmation — Non-GAAP EPS came in at $1.38 vs the prior-year quarter, and FY guidance was raised at both ends. The Q2 promise of Q3 YoY EPS growth held, and the raise removes the floor risk that was implied by the prior $4.80 low end.
Resolved positively
Dental merchandise growth turn — Not separately disclosed in the press release. Global Dental Distribution as a whole grew 4.8% (vs +1.1% in Q2), strongly implying merchandise has turned positive given the relative weight of merchandise within dental distribution, but the specific merchandise line item is not in the print.
Continue monitoring
CEO transition disclosures — The press release did not provide updated delineation of successor authority. Management discussed KKR board involvement and operational collaboration, which is adjacent, but the specific Albertini-vs-Popek question was not addressed in available disclosure.
Continue monitoring
Restructuring savings burn rate — Not separately quantified in the press release. The FY EPS raise of $0.05 at the midpoint is consistent with savings tracking at or modestly above the implied run rate, but specific Q3 savings dollars and the updated YTD total were not disclosed.
Continue monitoring

What to watch into next quarter

Q4 EPS implied by the raise — Raised FY midpoint of $4.92 vs Q1+Q2+Q3 cumulative EPS implies Q4 non-GAAP EPS of roughly $1.30+ (depends on Q1 base). Watch whether Q4 lands above the prior-year Q4 by a margin consistent with the raise, or whether the raise was front-loaded.

Distribution gross margin direction in Q4 — Gross margin fell 70bps QoQ to 30.7%. Watch whether the value-implant and medical-mix drag stabilizes or widens further. Sustained sequential gross margin compression would complicate the $200M operating income story even with revenue growth holding.

$200M value creation program phasing — Management framed it as "over the next few years" but did not specify 2026 vs 2027 vs 2028 contribution. Watch the Q4 call or 2026 outlook for a breakdown — back-end-loaded phasing is materially less valuable than front-end.

CEO succession resolution — Bergman retires at year-end. The next earnings cycle will be the first under new leadership; watch for clear naming of the operating CEO and whether the strategic framework (Bold+1 plus value creation program) is reaffirmed verbatim or reframed.

Sales-rep recruiting traction — Management cited competitor reps "knocking on our door." Watch FY2026 commentary for whether headcount growth in the sales organization is quantified, which would convert anecdote into a measurable competitive indicator.

Adjusted EBITDA growth reaffirmation vs raise — EBITDA growth guide stayed at mid-single digits despite the EPS raise, implying the EPS lift came from below-the-line items (interest, tax, share count) rather than operating leverage. Watch whether Q4 brings a quantitative EBITDA guide raise, which would be a stronger signal than the EPS-only raise delivered this quarter.

Sources

  1. Henry Schein Q3 2025 press release, Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/1000228/000100022825000063/exhibit991.htm
  2. Henry Schein Q3 2025 earnings call commentary (sourced via management quotes in extraction; no full transcript section available)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.